A Phase 2 interventional study of HLX208 in Brain Tumor, Primary, sponsored by Shanghai Henlius Biotech. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-03.
Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies in Brain Neoplasms with a site in China — 72 open to participants now, 83 under way, 6 of them phase 3. Brain Neoplasms · China.
Among the 179 studies in Brain Neoplasms with a site in China, this one is the 92nd largest by planned enrollment of the 142 interventional ones that give a count, is one of 13 that started in 2021, is one of 60 in phase 2, and was the 87th registered.
2,442 studies on the registry are indexed under Brain Neoplasms; 543 are open to participants now.
Browse Brain Neoplasms studies →72 of the 179 studies in Brain Neoplasms with a site in China are open now. Recruiting first, the newest first:
Beijing Inno Medicine Co., Ltd. · Sites in China, United States
Ages 18–70
Bristol-Myers Squibb · Sites in China, United States, Belgium and 10 more countries
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Peking University Third Hospital · Sites in China
Ages 18–70
Sun Yat-sen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 427 Brain Neoplasms studies recruiting now, 287 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 76 · Phase 3 22 · Phase 4 3
First in 1997; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 1,833 interventional studies indexed under Brain Neoplasms.
Median enrollment 60 across the 142 interventional studies, 358 across the 37 observational. Of the 41 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 179 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai Henlius Biotech, one of the names counted as Fosun Pharma. Under that name alone:
Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.
Fosun Pharma has 1 study filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Brain Neoplasms with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239115Phase 3Beijing Tiantan HospitalLevetiracetam for Seizure Prevention After Brain Tumor Surgery | 2027-01 |
| NCT06457906Phase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesSRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC | 2027-08-30 |
| NCT07446842Tongji HospitalConstruction of AI Model for Precision Imaging Diagnosis of Cranial Diseases | 2026-12 |
| NCT06231186Ruijin Hospitala Feasibility Study of iHD-SRT for BM | 2026-12 |
| NCT06793332Fudan UniversityBrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 179 studies in Brain Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HLX208
450mg bid po
ORR
Objective response rate(assessed by independent radiological review committee (IRRC) based on the RANO
Time frame: from first dose to the last patient was followed up for 6 month
PFS
Progression-free survival(PFS):assessed by IRRC and the investigator based on the RANO
Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),an average of about 1 year
DOR
Duration of response
Time frame: from the first occurrence of a documented CR or PR (whichever recorded earlier) to the time of first documented disease progression or death (whichever occurs first),an average of about 1 year
OS
Overall survival
Time frame: from the first dose to the time of death due to any cause,an average of about 2 year
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for May 2023, 17 months after the start.
Of 44 industry-sponsored phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 17 months is below that.
Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BRAF V600E Inhibitor HLX208